Press release
Biosimilars Market Size Growing at 24.7% CAGR, Set to Reach USD 143.6 Bn By 2031 | Pfizer Inc., Novartis AG (Sandoz), Amgen Inc., Biocon Ltd.
Request Sample Copy of the Report:
https://www.alliedmarketresearch.com/request-sample/162
The biosimilars market has been experiencing significant growth in recent years. Biosimilars are highly similar versions of approved biologic drugs, offering comparable safety, efficacy, and quality to the reference products.
The primary driving factors behind the biosimilars market growth include the expiry of patents for several biologic drugs, increasing healthcare costs, and the need for affordable treatment options.
Biosimilars provide an opportunity for cost savings and improved access to essential therapies. They can potentially reduce healthcare expenditures by offering lower-priced alternatives to expensive biologics.
Regulatory frameworks have been established in various countries to ensure the safety and efficacy of biosimilars. These frameworks include stringent comparability studies and clinical trials to demonstrate biosimilarity to the reference product.
Major therapeutic areas targeted by biosimilars include oncology, autoimmune diseases, and inflammatory disorders. Biosimilars have been developed for popular biologic drugs like monoclonal antibodies, insulin, erythropoietin, and growth hormones.
Market Segmentation:
By Product Type: Biosimilar products can be categorized based on the type of biologic drug they are designed to replicate. This includes monoclonal antibodies, insulin, erythropoietin, growth hormones, and others.
By Therapeutic Area: Biosimilars are developed for specific therapeutic areas or diseases. Common therapeutic areas targeted by biosimilars include oncology, autoimmune diseases (such as rheumatoid arthritis and psoriasis), inflammatory disorders (such as Crohn's disease and ulcerative colitis), and supportive care (such as anemia and growth disorders).
By Geography: The biosimilars market can be segmented by geographical regions, such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Market dynamics and regulatory landscapes vary across regions, impacting the adoption and growth of biosimilars.
By Distribution Channel: Biosimilar products can be distributed through various channels, including hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies. The choice of distribution channel can vary based on the product and the healthcare system in a particular region.
Request for Customization -
https://www.alliedmarketresearch.com/request-for-customization/162
Competitive Landscape:
Pfizer Inc.
Novartis AG (Sandoz)
Amgen Inc.
Biocon Ltd.
Celltrion Inc.
Samsung Bioepis Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Fresenius Kabi AG
Dr. Reddy's Laboratories Ltd.
Buy this Premium Research Report:
https://www.alliedmarketresearch.com/purchase-enquiry/162
VALUE PROPOSITIONS RELATED TO THE REPORT:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment.
Browse more latest healthcare reports:
Nerve Repair and Regeneration Market https://www.alliedmarketresearch.com/nerve-repair-and-regeneration-market
Ostomy Drainage Bags Market https://www.alliedmarketresearch.com/ostomy-drainage-bags-market
Computer-Aided Drug Discovery Market https://www.alliedmarketresearch.com/computer-aided-drug-discovery-market-A16823
Ambulatory X-Ray Devices Market https://www.alliedmarketresearch.com/ambulatory-x-ray-devices-market-A13405
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Size Growing at 24.7% CAGR, Set to Reach USD 143.6 Bn By 2031 | Pfizer Inc., Novartis AG (Sandoz), Amgen Inc., Biocon Ltd. here
News-ID: 3080409 • Views: …
More Releases from Allied Market Research
Fashion Events Market Size Worth USD $61.5 Billion by 2032, Growth Rate (CAGR) o …
According to a new report published by Allied Market Research, titled, "Fashion Events Market Size, Share, Competitive Landscape and Trend Analysis Report by Type, by Revenue Source, by Organizer: Global Opportunity Analysis and Industry Forecast, 2023-2032" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global fashion events market size was…
Sustainable Tourism Market Size Worth USD $11.4 Trillion by 2032, Growth Rate (C …
According to a new report published by Allied Market Research, titled, "Sustainable Tourism Market" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. In 2023, the coastal tourism segment occupied the largest market share as it is one of the most popular types of sustainable tourism locations in the world due to…
Pearl Jewelry Market Size to Hit US$ 42 Billion by 2031, Growing Almost 13.2% CA …
According to a new report published by Allied Market Research, titled, "Pearl Jewelry Market by Type, by Material, by Pearl Nature, by Pearl Source, by Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022-2031" The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global pearl jewelry market was valued at $12.8…
Lottery Market Projected to Acquire $430.4 Billion by 2031, Strong Growth at 3.8 …
According to a new report published by Allied Market Research, titled, "Lottery Market by Type, by Application: Global Opportunity Analysis and Industry Forecast, 2021-2031". The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. The global lottery market was valued at $300.6 billion in 2021, and is projected to reach $430.4 billion by…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
